REFERENCES
- Drouet L, Baudin B. Comment l'endothelium participate-t-il au controle du tonus vascularite? Rev Prat. 1988;38:2090–2094. [PUBMED], [INFOTRIEVE], [CSA]
- Davies MG, Hagen PO. The vascular endothelium: a new horizon. Ann Surg. 1993;218:593–609. [PUBMED], [INFOTRIEVE], [CSA]
- Pearson JD. The control of production and release of haemostatic factors in endothelial cells. Ballieres Clin Haematol. 1993;161:155–167. [CSA]
- Lazo JS, Lynch TJ, McCalister J. Bleomycin inhibition of angiotensin-converting enzyme activity from serum, lungs and cultured pulmonary artery endothelial cells. Am Rev Respir Dis. 1986;134:74–78. [CSA]
- Czaykowiski PM, Moore MJ, Tannock IF. High risk of vascular events in patients with urethelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol. 1998;160:1021. [CSA]
- Smith AC, Boyd MR. Effects of bis-chloronitrosourea (BCNU) on pulmonary and serum angiotensin-converting enzyme activity in rats. Biochem Pharmacol. 1989;32:3719–3722. [CSA], [CROSSREF]
- Adamson IYR, Orr FW, Young L. Effects of injury and repair of the pulmonary endothelium on lung metastasis after bleomycin. J Pathol. 1986;150:279–287. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Arbuck SG, Strauss H, Rowinsky E. A reassessment of cardiac toxicity associated with Taxol. J Natl Cancer Inst Monogr. 1993;15:117–130. [PUBMED], [INFOTRIEVE], [CSA]
- Roth BJ, Yeap BY, Wilding G, Kasimis B, McLeod D, Loehrer PJ. Taxol in advanced, hormone-refractory carcinoma of the prostate: a phase II trial of the Eastern Cooperative Oncology Group. Cancer. 1993;72:2457–2460. [PUBMED], [INFOTRIEVE], [CSA]
- Rowinski EK, Donehower RC. Drug therapy: Paclitaxel (Taxol). N Engl J Med. 1995;332:1004–1014. [CSA], [CROSSREF]
- Hortobagyi GN, Holmes FA, Theriault RL, Rahman Z, Buzdar AU. Combination chemotherapy with paclitaxel and doxorubicin for metastatic breast cancer. Semin Oncol. 1997;24:4(Suppl 11):11–19. [CSA]
- Martin M, Luch A, Ojeda B. Paclitaxel plus doxorubicin in metastatic breast cancer: preliminary analysis of cardiotoxicity. Semin Oncol. 1997;24:5(Suppl):17–30. [CSA]
- Carmichael J, Jones A, Hutchinson T. A phase II trial of epirubicin plus paclitaxel in metastatic breast cancer. United Kingdom Coordinating Committee for Cancer Research Breast Cancer Sub-Committee. Semin Oncol. 1997;24:5(Suppl 17):S17–S44. [PUBMED], [INFOTRIEVE], [CSA]
- Bristow Mr, Mason WJ, Billingham ME, Daniels JR. Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med. 1978;88:168–175. [PUBMED], [INFOTRIEVE], [CSA]
- Lefrak EA, Pitha J, Rosenhelm S, O'Bryan RM, Burges MA, Gottlieb JA. Adriamycin cardiomyopthy. Cancer Chemother Rep. 1975;6:203–208. [CSA]
- Unverferth DV, Fetters JK, Unverferth BJ, , et al. Human myocardial histologic characteristics in congestive heart failure. Circulation. 1983;68:1194–1200. [PUBMED], [INFOTRIEVE], [CSA]
- Innocenti F, Danesi R, Di-Paulo A. Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice. Drug-Metab-Dispos. 1995;23:713–717. [PUBMED], [INFOTRIEVE], [CSA]
- Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood. 1998;91:3527–3561. [PUBMED], [INFOTRIEVE], [CSA]
- Gryglewski RJ, Botting RM, Vane JR. Mediators produced by the endothelial cell. Hypertension. 1988;12:530–548. [PUBMED], [INFOTRIEVE], [CSA]
- Schafer AI. Vascular endothelium: in defence of blood fluidity. J Clin Invest. 1997;99:1143. [PUBMED], [INFOTRIEVE], [CSA]
- Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411–415. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- McGorisk GM, Treasure CB. Endothelial function in coronary heart disease. Curr Opin Cardiol. 1996;311–341. [CSA]
- Keizer HG, Pinedo HM, Schuurhuis GJ, Joenje H. Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther. 1990;47:219–231. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- McGuire WP, Rowinsky EK, Rosenshien NB. A unique antineoplastic agent with significant activity in advanced overian epithelial neoplasms. Ann Intern Med. 1989;111:273–279. [PUBMED], [INFOTRIEVE], [CSA]
- Mailloux A, Grenet K, Bruneel A, Beneteau-Burnat B, Vaubourdolle M, Baudin B. Anticancer drugs induce necrosis of human endothelial cells involving both oncosis and apoptosis. Eur J Cell Biol. 200;80:442–449. [CSA], [CROSSREF]